Home › Cancro al seno › Alabama
Studi clinici su Cancro al seno nello stato di Alabama
29 studi su Cancro al seno cercano partecipanti presso sedi nello stato di Alabama.
Città nello stato di Alabama
Testo ufficiale dello studio (inglese)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Central Alabama Research, Birmingham
In reclutamentoFase 3
Età da 18 a 100 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05827081A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06760819A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Alabama Oncology, Birmingham
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06369285PRE-ISPY Phase I/II Oncology Platform Program
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT05868226Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
- University of Alabama at Birmingham, Birmingham
In reclutamentoFase 2
Età 60 e oltre · Donne · Aggiornato il 30 set 2026 · NCT06105684A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Southern Cancer Center (SCC) ( Site 8000), Daphne
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07060807An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- University of Alabama At Birmingham Hospital, Birmingham
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07222267A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Daphne
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06103864Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
- The Kirklin Clinic, Birmingham
In reclutamento
Età da 18 a 90 · Donne · Aggiornato il 25 set 2026 · NCT06294574A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT06618287A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Alabama at Birmingham, Birmingham
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 22 set 2026 · NCT07287098Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- University of Alabama at Birmingham, Birmingham
In reclutamentoVolontari sani benvenuti
Età da 30 a 74 · Donne · Aggiornato il 21 set 2026 · NCT02620852A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Southern Cancer Center, PC, Daphne
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 set 2026 · NCT06492616Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06293898Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Birmingham Hematology Associates, Birmingham
In reclutamentoStudio osservazionale
Età da 18 a 99 · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07211178TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- University of Alabama, Birmingham
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 26 ago 2026 · NCT06533826Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Southern Cancer Center, Mobile
In reclutamentoFase 3
Età da 18 a 100 · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT05232916Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
- University of Alabama, Birmingham, Birmingham
In reclutamentoVolontari sani benvenuti
Età da 45 a 74 · Donne · Aggiornato il 31 lug 2026 · NCT05625659Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Uni of Alabama at Birmingham, Birmingham
In reclutamentoFase 1
Età da 18 a 100 · Tutti i sessi · Aggiornato il 29 lug 2026 · NCT06562192Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
- The University of Alabama, Birmingham
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 mag 2026 · NCT06855654I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Alabama at Birmingham, Birmingham
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 mag 2026 · NCT01042379Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 apr 2026 · NCT05297734De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- University of South Alabama Mitchell Cancer Institute, Mobile
In reclutamentoFase 3
Età da 50 a 70 · Tutti i sessi · Aggiornato il 23 apr 2026 · NCT04852887A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- University of Alabama at Birmingham, Birmingham
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 feb 2026 · NCT06099769Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
- The Kirklin Clinic, Birmingham
In reclutamentoFase 1 iniziale
Età 18 e oltre · Donne · Aggiornato il 26 gen 2026 · NCT03321045Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
- University of Alabama Birmingham, Birmingham
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 gen 2026 · NCT05693766Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- The University of Alabama at Birmingham, Birmingham
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 dic 2025 · NCT04722341RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
- University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham
In reclutamento
Età da 18 a 99 · Tutti i sessi · Aggiornato il 31 ott 2025 · NCT03643861SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 28 ott 2025 · NCT03452774Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.